Latest Articles
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer - Journal of Translational Medicine
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer Journal of Translational Medicine
Published: July 24, 2025, 9:25 p.m.
Clinical Pregnancy Outcomes in Young Women with Diminished Ovarian Reserve Undergoing Frozen Embryo Transfer: A Comprehensive Analysis with Exploratory Insights into Endometrial Aging - Frontiers
Clinical Pregnancy Outcomes in Young Women with Diminished Ovarian Reserve Undergoing Frozen Embryo Transfer: A Comprehensive Analysis with Exploratory Insights into Endometrial Aging Frontiers
Published: July 10, 2025, 7:26 p.m.
Radiomics analysis based on T2-weighed imaging and T2 mapping for staging endometrial fibrosis - Nature
Radiomics analysis based on T2-weighed imaging and T2 mapping for staging endometrial fibrosis Nature
Published: July 8, 2025, 9:36 a.m.
Integrating Deep Learning and Clinical Characteristics for Early Prediction of Endometrial Cancer Using Multimodal Ultrasound Imaging: A Multicenter Study - Frontiers
Integrating Deep Learning and Clinical Characteristics for Early Prediction of Endometrial Cancer Using Multimodal Ultrasound Imaging: A Multicenter Study Frontiers
Published: June 19, 2025, 2:09 p.m.
Managing menstrual disorders in young women – key points for GPs - Pulse Today
Managing menstrual disorders in young women – key points for GPs Pulse Today
Published: June 12, 2025, 4:13 p.m.
Leveraging epigenetic aberrations in the pathogenesis of endometriosis: From DNA methylation to non-coding RNAs - Frontiers
Leveraging epigenetic aberrations in the pathogenesis of endometriosis: From DNA methylation to non-coding RNAs Frontiers
Published: June 9, 2025, 4:59 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo
Published: June 2, 2025, 6:30 p.m.
Link copied to clipboard!